Goodbye, Kidney Disease.
Hello, Kidney Health.
Traditional clinical kidney measurements are flawed.
Physicians typically look at estimated GFR and urinary albumin creatinine ratio levels, but they are inadequate in identifying those select patients who are more likely to experience progressive decline in kidney function.
That changes with kidney bioprognosis™.
We’ve engineered a new solution that successfully enables assessment of risk (high, moderate, low) for progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease (stages 1-3b). By catching it early, clinicians will be able to implement more appropriate care plans when it can make the most difference for their patients.
Our FDA-approved product, kidneyintelX.dkd, is at the core of our solution offering.
With kidneyintelX.dkd, we take diverse and proprietary data inputs and maximize their value through our AI-enabled algorithm. This allows us to generate a risk result and identify those patients who are at most risk for progressive decline in kidney function.
According to our clinical study, patients fall within 1 of 3 risk levels (low, moderate, high) for disease progression. By risk stratifying all type 2 diabetes patients with early-stage CKD, clinicians will have more information to determine which patients can be maintained on their current treatment plan, who will need a little more special attention, and who will require more intensive changes in care.
Our out-of-the-gate focus: Diabetic Kidney Disease.
Diabetes is the leading cause of chronic kidney disease, representing nearly 40% of its cases. That’s why our first priority is diabetic kidney disease.
diabetesjournals.org. Accessed 3.2024.
And our test platform eliminates the grey area common in diabetic kidney disease.
Currently, clinicians are unable to determine which of the 1 in 4 patients with type 2 diabetes and chronic kidney disease are at the highest risk for progressive decline in kidney function – vs those who are at lower risk. The FDA-authorized kidneyintelX.dkd test is the only test that identifies those patients who are at higher-to-lower risk to help you determine the best treatment plan.
The KidneyIntelX technology. Designed to be scalable.
Today, we are focused on diabetic kidney disease. In the future, we’ll continue our focus on kidney disease and its comorbidities by expanding our test platform to include screening, diagnosis, next generation prognostic tools, and the monitoring of efficacy and prediction of response to existing and novel therapeutics.
We’re fortunate to have great collaborators.
And more partnerships are in the works.
“Diabetic kidney disease is largely an asymptomatic disease, and the tools we have been using to screen and stage the disease have not provided us with accurate or timely information. When the patient and the physician both see the (KidneyIntelX technology) prognostic results, in black and white, it creates the space and the forum for us to talk about a health issue that has been largely invisible and needs to be corrected.”
“Our partnership with Renalytix aims to improve kidney risk stratification in type-2 diabetes… their (solution) uses artificial intelligence to evaluate the combination of important kidney function biomarkers and electronic health record information.”
“Renalytix is linking molecular mechanisms and patient data with educational tools to drive a rigorous, clinically-validated and new model of care in kidney disease.”*Title provided for identification purposes only. The views and opinions expressed are those of the individual only and do not necessarily reflect the positions of University of Michigan.
“Together, we are committed to revolutionizing kidney care… by identifying patients with significant unmet needs and providing them with more personalized interventions.”
